Pliant Therapeutics appoints Thomas McCourt and Darren Cline to Board of Directors

PLIANT THERAPEUTICS, INC.

Board expanded from 8 to 10 members; McCourt (Class II) and Cline (Class I) appointed effective March 6, 2023.
Both deemed independent; McCourt joins Compensation Committee, Cline joins Audit Committee.
Each receives annual retainer of $40,000; McCourt $5,000 for Comp Committee, Cline $7,500 for Audit Committee.
Each granted option to purchase 22,000 shares, vesting monthly over three years.
Standard indemnification agreements entered into with both new directors.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Darren Cline

Director

PLRX · PLIANT THERAPEUTICS, INC.

Effective: 2023-03-06
Filed: March 8, 2023, 6:59 PM ET

the Board appointed, upon the recommendation of the Nominating and Corporate Governance Committee of the Board (the “Nominating and Governance Committee”), each of Thomas McCourt and Darren Cline to fill the Class II and Class I vacancies on the Board, respectively.

Appointed

Thomas McCourt

Director

PLRX · PLIANT THERAPEUTICS, INC.

Effective: 2023-03-06
Filed: March 8, 2023, 6:59 PM ET

the Board appointed, upon the recommendation of the Nominating and Corporate Governance Committee of the Board (the “Nominating and Governance Committee”), each of Thomas McCourt and Darren Cline to fill the Class II and Class I vacancies on the Board, respectively.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Darren Cline was appointed as Director at PLIANT THERAPEUTICS, INC..

Action: appointed
Role: Director

Exact text from the filing

the Board appointed, upon the recommendation of the Nominating and Corporate Governance Committee of the Board (the “Nominating and Governance Committee”), each of Thomas McCourt and Darren Cline to fill the Class II and Class I vacancies on the Board, respectively.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Thomas McCourt was appointed as Director at PLIANT THERAPEUTICS, INC..

Action: appointed
Role: Director

Exact text from the filing

the Board appointed, upon the recommendation of the Nominating and Corporate Governance Committee of the Board (the “Nominating and Governance Committee”), each of Thomas McCourt and Darren Cline to fill the Class II and Class I vacancies on the Board, respectively.

View on SEC.gov

PLIANT THERAPEUTICS, INC. filing history →

Source: SEC EDGAR

accession 0001193125-23-064549

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.